👋
Is this profile yours? Take control to keep your details current, set fees, and respond to reviews.
This page is aggregated from public sources.
Claim this profile →
✓ Verified
Trust score 98/100
Accepting new patients
Dr
Dr Amarnath Challapalli
Oncology
English
Hindi
Telugu
13,357+
Patients seen
6
Years in practice
4
Publications
3
Languages spoken
About
Dr. Amarnath Challapalli is a Consultant Clinical Oncologist at Bristol Cancer Institute, University Hospitals Bristol NHS Foundation Trust. He specialises in the management of urological cancers (prostate, bladder, renal and penile cancers) and non-melanomatous skin cancer with radiotherapy, brachytherapy, chemotherapy and immunotherapy; in both NHS and private practice. He is the Clinical Director of Bristo Cancer Institute. He organises and lectures in the skin cancer study day for the Royal College of Radiologists and is a faculty member on other courses for the college; demonstrating his excellence and ongoing passion for his sub-speciality. He is also a panel member of Mirrors in Medicine, an International Case-based professional development platform. He has been chosen as a Prostate Cancer UK (PCUK) Clinical Champion and is leading on a project to improve access to PSMA PET scans and Lutetium based radioligand therapy.
Dr. Challapalli undertook his medical and postgraduate training in clinical oncology in India and in the UK, achieving Fellowship of the Royal College of Radiologists. He subsequently completed a PhD at Imperial College, London in January 2014; testament to his passion and dedication to medical research alongside his practice. His research focused on the translation of novel PET tracers looking at cell proliferation, apoptosis and choline metabolism into clinical studies to look at early response assessment to treatment. His work has been published in peer-reviewed journals and presented at national and international meetings.
His research interests include functional imaging for urological cancers, stereotactic radiotherapy, brachytherapy, image guidance and exploring chemotherapy & immunotherapy combinations. He has developed and leads the brachytherapy service for non-melanoma skin cancers at the Bristol Cancer Institute. He is the UK Chief Investigator for the adjuvant Cemiplimab trial in high risk squamous cell carcinoma (C-POST trial) and a Co-Chief Investigator of the national multicentre ACE trial in prostate cancer and EPIC trial in penile cancer.
Dr. Challapalli is one of the highly skilled multi-disciplinary team at GenesisCare Bristol where he sees private patients; using his knowledge and expertise to not only provide the best physical outcomes for patients but also make sure that each patient's individual cancer journey is tailored exactly to their needs.
Diseases, Medical Tests and Treatments
• Radiotherapy (IMRT, VMAT, Stereotactic Radiotherapy(SABR))
• Brachytherapy
• Chemotherapy
• Immunotherapy
• Urological cancers
• Non-melanomatous skin cancer
Dr. Challapalli undertook his medical and postgraduate training in clinical oncology in India and in the UK, achieving Fellowship of the Royal College of Radiologists. He subsequently completed a PhD at Imperial College, London in January 2014; testament to his passion and dedication to medical research alongside his practice. His research focused on the translation of novel PET tracers looking at cell proliferation, apoptosis and choline metabolism into clinical studies to look at early response assessment to treatment. His work has been published in peer-reviewed journals and presented at national and international meetings.
His research interests include functional imaging for urological cancers, stereotactic radiotherapy, brachytherapy, image guidance and exploring chemotherapy & immunotherapy combinations. He has developed and leads the brachytherapy service for non-melanoma skin cancers at the Bristol Cancer Institute. He is the UK Chief Investigator for the adjuvant Cemiplimab trial in high risk squamous cell carcinoma (C-POST trial) and a Co-Chief Investigator of the national multicentre ACE trial in prostate cancer and EPIC trial in penile cancer.
Dr. Challapalli is one of the highly skilled multi-disciplinary team at GenesisCare Bristol where he sees private patients; using his knowledge and expertise to not only provide the best physical outcomes for patients but also make sure that each patient's individual cancer journey is tailored exactly to their needs.
Diseases, Medical Tests and Treatments
• Radiotherapy (IMRT, VMAT, Stereotactic Radiotherapy(SABR))
• Brachytherapy
• Chemotherapy
• Immunotherapy
• Urological cancers
• Non-melanomatous skin cancer
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Dr Amarnath Challapalli
Education & training
-
2010–2016 MD · Medicine and Surgery
-
2016–2020 Residency · Oncology
-
2020–2021 Fellowship · Subspecialty training
Career & appointments
-
2020-09–2021-08 Junior consultant
Licenses & insurance
Medical licenses
— Organización Médica Colegial de España (OMC)
Board certifications
European Board of Oncology
Malpractice insurance:
HDI Global · 1,000,000 EUR coverage
· No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 386 |
| Annual physical exam | 99395 | 652 |
| Vaccination administration | 90471 | 2,684 |
| Minor procedure (skin) | 17110 | 931 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 60 min | in_clinic | 360.00 EUR |
| Minor procedure (skin) | 90 min | in_clinic | 270.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 19 · i10: 10
-
Outcomes of Oncology in adults — a multi-centre cohort
DOI: 10.2159/euroclin.2025.0 · PMID: 30259292 · cited by 10
-
European registry analysis of Oncology outcomes
DOI: 10.3198/euroclin.2024.1 · PMID: 36984705 · cited by 88
-
Outcomes of Oncology in adults — a multi-centre cohort
DOI: 10.2944/euroclin.2023.2 · PMID: 34807355 · cited by 126
Invited talks
- Practical updates in Oncology European Annual Congress (Oncology) · Vienna · 2024 · invited
- Single-centre experience in Oncology National Society Meeting · · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Oncology — · EuroClinics Patient Choice · 2025 · regional
- 🏆 Excellence in Patient Care · National Society · 2024 · national
- 🏆 Young Investigator Award · European Society · 2023 · international
Society memberships
- WONCA Europe — Family Doctors — Member · since 2021
- national college of family doctors — Member · since 2021
- European Union of Medical Specialists (UEMS) — Member · since 2021
Patient reviews
- Bedside Manner
- 5.00
- Knowledge
- 5.00
- Wait Time
- 4.75
- Staff Friendliness
- 5.00
- Ease Of Appointment
- 4.90
- Value For Money
- 4.92
- Would Recommend Pct
- 99
-
★ 5 verified visit
“Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.”
-
★ 5 verified visit
“Took time to listen and reviewed all my previous results. I would absolutely recommend.”
-
★ 4 verified visit
“Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.”
Articles by this doctor
- Patient education Patient guide to Oncology
- Awareness When should you see a oncology?
For international patients
- Coordinator
- Patient liaison · amarnath.challapalli@euroclinics.example
- Accepted intl insurance
- Allianz Worldwide · AXA Global · BUPA Global · Cigna Global
